Institut De Recherches Internationales Servier IRIS

CompanyFrance

Institut De Recherches Internationales Servier IRIS develops 3 assets, the furthest in phase 3 (Dapagliflozin/Bisoprolol fumarate in heart failure). Mostly small molecule; based in France.

3
Assets
Furthest stage
Phase 3
1
Trial
3
Signals

Pipeline

3
  • Dapagliflozin/Bisoprolol fumarate

    Combines SGLT2 inhibition and beta-1 adrenergic blockade to treat heart failure.

    Phase 3, Small molecule, heart failure

  • Dapagliflozin/Bisoprolol fumarate/Eplerenone

    Combines SGLT2 inhibition, beta-1 adrenergic blockade, and mineralocorticoid receptor antagonism to treat heart failure.

    Phase 3, Small molecule, heart failure

  • Dapagliflozin/Eplerenone

    Combines SGLT2 inhibition and mineralocorticoid receptor antagonism to treat heart failure.

    Phase 3, Small molecule, heart failure

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals3
  • Similar companies6

Intelligence